Professor, Medicine, UCSF School of Medicine
Pulmonology
Dr. Stephen C. Lazarus, MD
|
|
Give Review
Stephen Lazarus is an expert in the field of Pulmonology. He went to medical school at University of California Irvine School of Medicine. University of California Irvine School of Medicine has a rank of 45 in research and a 62 in primary care He over the years received 1 awards: "CMS Meaningful Use Stage 1 Certification". Doctor Stephen C. Lazarus, MD is a published doctor and has 88 publications published. The lastest was: 'Neutrophil elastase and elastase-rich cystic fibrosis sputum degranulate human eosinophils in vitro.' He is registered with Medicare.
Publications
- Early Administration of Azithromycin and Prevention of Severe Lower Respiratory Tract Illnesses in Preschool Children With a History of Such Illnesses: A Randomized Cl...
- Pharmacodynamic genome-wide association study identifies new responsive loci for glucocorticoid intervention in Asthma.
- Lipoxin Generation is Related to Soluble Epoxide Hydrolase Activity in Severe Asthma.
- Simvastatin for the Prevention of Exacerbations in Moderate-to-Severe COPD.
- Effect of Vitamin D3 on Asthma Treatment Failures in Adults With Symptomatic Asthma and Lower Vitamin D Levels: The VIDA Randomized Clinical Trial.
- Predictors of COPD Exacerbation Reduction in Response to Daily Azithromycin Therapy.
- Tumour necrosis factor receptor 75 and risk for COPD exacerbation in the azithromycin trial.
- P2X7-regulated protection from exacerbations and loss of control is independent of Asthma maintenance therapy.
- Long-term comparative immunogenicity of protein conjugate and free polysaccharide pneumococcal vaccines in Chronic obstructive pulmonary disease.
- Genomewide association between GLCCI1 and response to glucocorticoid therapy in Asthma.
- Objective airway monitoring improves Asthma control in the cold and flu season: a cluster randomized trial.
- Clinical practice. Emergency treatment of Asthma.
- Management of chronic obstructive pulmonary disease: moving beyond the Asthma algorithm.
- Interaction of ambient air pollution with Asthma medication on exhaled nitric oxide among Asthmatics.
- Mild persistent Asthma: is any treatment needed?
- Epithelial mucin stores are increased in the large airways of smokers with airflow obstruction.
- Allergic rhinitis, Asthma, airway biology, and chronic obstructive pulmonary disease in AJRCCM in 2004.
- Cystic fibrosis, pediatrics, control of breathing, Pulmonary physiology and anatomy, and surfactant biology in AJRCCM in 2004.
- Systemic effect comparisons of six inhaled corticosteroid preparations.
- Where do leukotriene modifiers fit in Asthma management?
- The role of mast cell-derived mediators in airway function.
- [Characteristics and evolutive data of Chronic respiratory diseases after respiratory intensive care. Evaluation of the Pneumology Department of the Pavillon Saint-Fra...
- Role of inflammation and inflammatory mediators in airways Disease.
- Characterization of tracheal mast cell reactions in vivo. Inhibition by a beta-adrenergic agonist.
- Antigen-induced airway hyperresponsiveness and Pulmonary inflammation in allergic dogs.
- Rational therapy of acute Asthma.
- Cutaneous mast cell heterogeneity: response to antigen in atopic dogs.
- Mast cells and cell-to-cell interactions in airways.
- Tryptase and chymase: comparison of extraction and release in two dog mastocytoma lines.
- Mitogen-inducible prostaglandin G/H synthase is expressed in canine mastocytoma cells.
- Dog mastocytoma cells secrete a 92-kD gelatinase activated extracellularly by mast cell chymase.
- Authentic 17 kDa tumour necrosis factor alpha is synthesized and released by canine mast cells and up-regulated by stem cell factor.
- Selective adhesion of mast cells to tracheal epithelial cells in vitro.
- Purification and characterization of dog mastocytoma chymase: identification of an octapeptide conserved in chymotryptic leukocyte proteinases.
- Dog mastocytoma tryptase: affinity purification, characterization, and amino-terminal sequence.
- The effects of epithelial cell supernatant on contractions of isolated canine tracheal smooth muscle.
- Dog mastocytoma proteoglycans: occurrence of heparin and oversulfated chondroitin sulfates, containing trisulfated disaccharides, in three cell lines.
- Heterogeneity of intact granules purified from canine mastocytoma cell lines.
- Effect of inhibitors on histamine release from mast cells recovered by bronchoalveolar lavage in basenji-greyhound and mongrel dogs.
- Tobacco smoke releases performed mediators from canine mast cells and modulates prostaglandin production.
- Prostaglandin D2 production and identification of prostaglandin H synthase within canine mast cell granule.
- Heparin inhibits histamine release from canine mast cells.
- A new perspective on concepts of Asthma severity and control.
- Effect of beta-adrenergic stimulation on experimental canine anaphylaxis in vivo.
- Mast cell tryptase and chymase reverse airway smooth muscle relaxation induced by vasoactive intestinal peptide in the ferret.
- Mast cell tryptase causes airway smooth muscle hyperresponsiveness in dogs.
- Chymase and tryptase in dog mastocytoma cells: asynchronous expression as revealed by enzyme cytochemical staining.
- Diagnosis and management of Asthma.
- Mast cell chymase. A potent secretagogue for airway gland serous cells.
- Antileukotrienes and laboratory models of Asthma.
- Inhaled corticosteroid reduction and elimination in patients with persistent Asthma receiving salmeterol: a randomized controlled trial.
- Safety and clinical efficacy of zileuton in patients with chronic Asthma.
- An evaluation of colchicine as an alternative to inhaled corticosteriods in moderate Asthma. National Heart, Lung, and Blood Institute's Asthma Clinical Research Network.
- Predicting worsening Asthma control following the common cold.
- Functional and morphologic characterization of mast cells recovered by bronchoalveolar lavage from Basenji greyhound and mongrel dogs.
- Safety and reproducibility of sputum induction in Asthmatic subjects in a multicenter study.
- Inflammation, inflammatory mediators, and mediator antagonists in Asthma.
- Human eosinophils induce mucin production in airway epithelial cells via epidermal growth factor receptor activation.
- The utility of peak flow, symptom scores, and beta-agonist use as outcome measures in Asthma clinical research.
- Long-acting beta2-agonist monotherapy vs continued therapy with inhaled corticosteroids in patients with persistent Asthma: a randomized controlled trial.
- Effect of polymorphism of the beta(2)-adrenergic receptor on response to regular use of albuterol in Asthma.
- Neutrophil elastase and elastase-rich Cystic fibrosis sputum degranulate human eosinophils in vitro.
- Comparison of regularly scheduled with as-needed use of albuterol in mild Asthma. Asthma Clinical Research Network.
- Issues in the use of inhaled glucocorticoids. The Asthma Clinical Research Network.
- The effect of polymorphisms of the beta(2)-adrenergic receptor on the response to regular use of albuterol in Asthma.
- The clinical trials in the initial five-year award period of the Asthma Clinical Research Network.
- Relationship between airway inflammation, hyperresponsiveness, and obstruction in Asthma.
- The leukotriene receptor antagonist zafirlukast inhibits sulfur dioxide-induced bronchoconstriction in patients with Asthma.
- Use of regularly scheduled albuterol treatment in Asthma: genotype-stratified, randomised, placebo-controlled cross-over trial.
- Airway tissue mast cells in persistent Asthma: predictor of treatment failure when patients discontinue inhaled corticosteroids.
- Combination therapy with a long-acting beta-agonist and a leukotriene antagonist in moderate Asthma.
- beta-Adrenergic receptor polymorphisms and response to salmeterol.
- Daily versus as-needed corticosteroids for mild persistent Asthma.
- Sputum eosinophil counts predict Asthma control after discontinuation of inhaled corticosteroids.
- The Predicting Response to Inhaled Corticosteroid Efficacy (PRICE) trial.
- Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in Asthma.
- An official American Thoracic Society/European Respiratory Society statement: Asthma control and exacerbations: standardizing endpoints for clinical Asthma trials and ...
- Associations between air pollution and peak expiratory flow among patients with persistent Asthma.
- Significant variability in response to inhaled corticosteroids for persistent Asthma.
- Barriers to patient-clinician collaboration in Asthma management: the patient experience.
- Effect of beta2-adrenergic receptor polymorphism on response to longacting beta2 agonist in Asthma (LARGE trial): a genotype-stratified, randomised, placebo-controlled...
- Impact of race on Asthma treatment failures in the Asthma clinical research network.
- Azithromycin for prevention of exacerbations of COPD.
- Randomized trial of zileuton for treatment of COPD exacerbations requiring hospitalization.
- Tiotropium bromide step-up therapy for adults with uncontrolled Asthma.
- A trial of clarithromycin for the treatment of suboptimally controlled Asthma.
- Influence of lightweight ambulatory oxygen on oxygen use and activity patterns of COPD patients receiving long-term oxygen therapy.
Schools
University Of California Irvine College Of Medicine
San Francisco General Hospital
University Of Calfornia San Francisco
Procedures Preformed
- Bronchoscopy
Conditions Treated
- Asthma
- Atelectasis
- Bronchiectasis
- Bronchiolitis
- View All
Doctors Specialties
- Pulmonology
Accepted Insurances
Awards
- CMS Meaningful Use Stage 1 Certification
Education
-
UCSF -
University of California Irvine School of Medicine
Hospital
-
San Francisco General Hospital and Trauma Center -
UCSF Medical Center
Drug Facts
| NPI NUMBER | 1659324531 | |
| NPPES Provider LastName | LAZARUS | |
| NPPES Provider FirstName | STEPHEN | |
| NPPES Provider ZIPCode | 941432202 | |
| NPPES Provider State | CA | |
| Specialty Description | Pulmonary Disease | |
| Total Claim Count | 578.0 | |
| Distinct Opioid Count | 0.0 | |
| Opioid Claim Count | 0.0 | |
| Percent Opioid Claims | 0.0 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1659324531 |
| Last Name Of The Provider | LAZARUS |
| First Name Of The Provider | STEPHEN |
| View All |
Similar Doctors
|
|
Dr. Homer A. Boushey, MD
 This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Rachel H. Dotson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey A. Golden, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Nicole A. Gonzales, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Adithya Cattamanchi, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Meshell D. Johnson, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Payam Nahid, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Michael J. Lafemina, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jeffrey K. Tobias, MD |
|
|
Dr. Robert M. Grant, MD |